Brown Advisory’s Amylyx Pharmaceuticals AMLX Stock Holding History

Brown Advisory’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Hold	19,930	–	–	﹤0.01%	1234
2026 Q1	$277K	Hold	19,930	–	–	﹤0.01%	1236
2025 Q4	$241K	Hold	19,930	–	–	﹤0.01%	1285
2025 Q3	$271K	Hold	19,930	–	–	﹤0.01%	1237
2025 Q2	$128K	Hold	19,930	–	–	﹤0.01%	1323
2025 Q1	$70.6K	Hold	19,930	–	–	﹤0.01%	1305
2024 Q4	$75.3K	Sell	19,930 -20	-0.1%	-$94	﹤0.01%	1321
2024 Q3	$64.6K	Sell	19,950 -11	-0.1%	-$25	﹤0.01%	1246
2024 Q2	$37.9K	Hold	19,961	–	–	﹤0.01%	1218
2024 Q1	$56.7K	Buy	19,961 +6,500	+48%	+$85K	﹤0.01%	1224
2023 Q4	$198K	Hold	13,461	–	–	﹤0.01%	1164
2023 Q3	$246K	Hold	13,461	–	–	﹤0.01%	1059
2023 Q2	$290K	Sell	13,461 -5,000	-27%	-$135K	﹤0.01%	1019
2023 Q1	$542K	Sell	18,461 -14,980	-45%	-$520K	﹤0.01%	894
2022 Q4	$1.24M	Sell	33,441 -10,000	-23%	-$355K	﹤0.01%	700
2022 Q3	$1.22M	Buy	+43,441	New	+$1.08M	﹤0.01%	667

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Brown Advisory's AMLX Position: Q2 2026 in Review

Brown Advisory held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 19,930 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1234.

Brown Advisory first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.24M in Q4 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Brown Advisory held 19,930 shares of Amylyx Pharmaceuticals worth $358K as of Q2 2026.
Brown Advisory left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1234 holding.
Brown Advisory first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Brown Advisory's Amylyx Pharmaceuticals position peaked at $1.24M in Q4 2022.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.